Home › Funds › Rock Springs Capital Management LP › BBIO
Rock Springs Capital Management LP position in BBIO
BRIDGEBIO PHARMA INC · Health Care
Rock Springs Capital Management LP reported holding 192,250 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$12.7M, representing 0.68% of its reported portfolio and ranking #47 among its reported holdings. Rock Springs Capital Management LP has disclosed BBIO holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Rock Springs Capital Management LP's BBIO position evolved
Rock Springs Capital Management LP first disclosed a stake in BBIO in Q3 2025 at 85,000 shares (US$4.4M). The position peaked in Q3 2026 at 192,250 shares, worth US$12.7M. Across 5 filings, Rock Springs Capital Management LP increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 192,250 shares valued at US$12.7M — an increase of 47,500 shares quarter over quarter.. Notable position changes include a 33% increase in Q3 2026 (shares rose 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 85.00K | $4.41M | New |
| Q4 2025 | 103.50K | $7.92M | Add |
| Q1 2026 | 128.25K | $9.52M | Add |
| Q2 2026 | 144.75K | $10.78M | Add |
| Q3 2026 | 192.25K | $12.65M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 42 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 14.25M sh · $937.45M · Q3 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M sh · $741.02M · Q2 2026
- Two Sigma Investments 3.66M sh · $240.83M · Q3 2026
- Aisling Capital Management LP 3.09M sh · $203.30M · Q3 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 104.89M sh · $162.63M · Q3 2026
- Paradigm Biocapital Advisors LP 2.35M sh · $154.49M · Q3 2026
- SC US (TTGP), LTD. 1.86M sh · $122.41M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.55M sh · $115.31M · Q2 2026
More on Rock Springs Capital Management LP
FAQ
How long has Rock Springs Capital Management LP held BBIO?
Rock Springs Capital Management LP has disclosed BBIO holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Rock Springs Capital Management LP's current position in BBIO?
As of Q3 2026, Rock Springs Capital Management LP holds 192.25K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $12.65M, representing 0.68% of its reported portfolio and ranking #47.
Has Rock Springs Capital Management LP been buying or selling BBIO?
In the latest 13F filing (Q3 2026), Rock Springs Capital Management LP increased its position in BBIO. The position peaked in Q3 2026 at 192.25K shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.